Rahul Ghiya*, Sanghita Layek and A Shobana

Department of Neurocritical Care, Institute of Neuroscience, Kolkata, West Bengal, India

*Corresponding Author: Rahul Ghiya, Department of Neurocritical Care, Institute of Neuroscience, Kolkata, West Bengal, India.

Received: January 11, 2024; Published: January 31, 2024

Abstract

Hyperammonemia manifests clinically as mild cognitive impairment to coma and even death. It happens due to both hepatic metabolic disorders or non-hepatic causes. Perampanel is an antiepileptic drug metabolized by hepatic enzymes.We here report a patient of CNS lupus who presented with NCSE and developed hyperammonemia after receiving the loading dose of perampanel. No definite mechanism has been able to explain the correlation between perampanel and hyperammonemia. The blood ammonia levels came down to the normal range after stopping the medication. However, even after the stoppage of perampanel and normalization of ammonia, her condition and NCSE remains the same. We suggest serum ammonia levels should be done before starting perampanel in any patient with a constant monitoring of ammonia levels at regular intervals. However, more cases are required to understand the mechanism of action, risk factors and establish monitoring protocols in patients for perampanel therapy.

Keywords: Hyperammonemia; Perampanel; NCSE; Neurological Manifestations

References

1. Rimsha Ali; Shivaraj Nagalli. “Hyperammonemia” (2023).
2. Fatih Ezgu. “Inborn Errors of Metabolism”. Advances in Clinical Chemistry 73 (2016): 195-250.
3. Pegg EJ and Zaman F. “Sodium valproate-related hyperammonaemic encephalopathy”. BMJ Case Reports (2014): bcr2014203899.
4. Gwendolyn A., et al. “Therapeutic Drug Monitoring of Newer Antiepileptic Drugs”. Clinical Challenges in Therapeutic Drug Monitoring (2016).
5. Odigwe CC., et al. “Noncirrhotic hyperammonemia causing relapsing altered mental status”. Archive of "Proceedings (Baylor University. Medical Center) 4 (2015):472-474.
6. Hawkes ND., et al. “Non-hepatic hyperammonaemia: an important, potentially reversible cause of encephalopathy”. Postgraduate Medical Journal 913 (2001):717-722.
7. Weng TI., et al. “Unusual causes of hyperammonemia in the ED”. The American Journal of Emergency Medicine 2 (2004):105-107.
8. Crisan E and Ramachandran TS. “Hyperammonemia”. Medscape.
9. Itoh H., et al. “Correlation between plasma ammonia level and serum trough concentration of free valproic acid in patients with epilepsy”. Biological and Pharmaceutical Bulletin 6 (2012): 971-4.
10. Noh Y., et al. “Topiramate increases the risk of valproic acid-induced encephalopathy”. Epilepsia 1 (2013): e1‐e4.
11. Roh SY., et al. “Valproic Acid-induced Hyperammonemic Encephalopathy Promoted by Levetiracetam”. Journal of Epilepsy Research 2 (2014):82‐84.
12. Walker V. “Ammonia metabolism and hyperammonemic disorders”. Advances in Clinical Chemistry 67 (2014): 73-150.
13. Adams EN., et al. “Carbamazepine-induced hyperammonemia”. American Journal of Health-System Pharmacy 16 (2009): 1468‐1470.
14. Epilepsy Derek G., et al. “Medical Pharmacology and Therapeutics (Fifth Edition) (2018).
15. Marques P., et al. “Hyperammonemic Encephalopathy Associated with Perampanel: Case Report and Discussion”. Canadian Journal of Neurological Sciences3 (2021): 438-439.

Citation

Citation: Rahul Ghiya., et al. “Non-hepatic Hyperammonemia with Loading Dose of Perampanel in a Case of CNS Lupus Presenting with Non-Convulsive Status Epilepticus". Acta Scientific Neurology 7.2 (2024): 46-49.

Copyright

Copyright: © 2024 Rahul Ghiya., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.